Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Thyroid : Official Journal of the American Thyroid Association
|
November 14, 2017
Urinary Iodine, Perchlorate, and Thiocyanate Concentrations in U.S. Lactating Women
Sun Y Lee, Alicia M McCarthy, Hindi Stohl, et al.
Journal of Hematology & Oncology
|
July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Jorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Michael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Annals of Hematology
|
March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Michael Heuser, B Douglas Smith, Walter Fiedler, et al.
Leukemia
|
December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Annals of Hematology
|
April 30, 2022
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Mikkael A Sekeres, Michael Schuster, Magalie Joris, et al.
JCI Insight
|
November 3, 2018
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR
Spencer C Behr, Javier E Villanueva-Meyer, Yan Li, et al.
Leukemia
|
August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
American Journal of Hematology
|
August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Thyroid : Official Journal of the American Thyroid Association
|
November 14, 2017
Urinary Iodine, Perchlorate, and Thiocyanate Concentrations in U.S. Lactating Women
Sun Y Lee, Alicia M McCarthy, Hindi Stohl, et al.
Journal of Hematology & Oncology
|
July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Jorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Michael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Annals of Hematology
|
March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Michael Heuser, B Douglas Smith, Walter Fiedler, et al.
Leukemia
|
December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Annals of Hematology
|
April 30, 2022
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Mikkael A Sekeres, Michael Schuster, Magalie Joris, et al.
JCI Insight
|
November 3, 2018
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR
Spencer C Behr, Javier E Villanueva-Meyer, Yan Li, et al.
Leukemia
|
August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
American Journal of Hematology
|
August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Page
of 2